Biotech: Page 2


  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna vaccine sales surpass expectations as company looks to fall boosters

    The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

    By May 4, 2022
  • Image attribution tooltip
    Regeneron

    Regeneron tries to shake off fall in COVID drug sales with first quarter earnings

    Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S. revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread.

    By Kristin Jensen • May 4, 2022
  • Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • Image attribution tooltip
    utah778 via Getty Images

    Spero to lay off 75% of workforce, change strategy after FDA challenges study results

    Agency statisticians took a different view of the Phase 3 results the biotech was relying on to support approval of a new antibiotic, an announcement that triggered the sector's latest restructuring.

    By May 4, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen CEO to step down as company pulls back from Alzheimer's drug

    Michel Vounatsos, Biogen's CEO since 2017, will be replaced as the company "substantially" eliminates the commercial workforce around Aduhelm, which has generated paltry sales in the face of resistance from insurers and doctors.

    By Updated May 3, 2022
  • Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    A cancer biotech attracts another deep-pocketed partner in Gilead

    Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."

    By May 2, 2022
  • Image attribution tooltip
    AbbVie

    AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis

    Executives on Friday said that the company's three-drug therapy, a possible threat to Vertex's top-selling medicine Trikafta, didn't meet expectations in a key study. A new combination could start testing next year, however.

    By April 29, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    After setbacks, a gene therapy company mulls a sale

    Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs.

    By April 28, 2022
  • Image attribution tooltip
    400tmax via Getty Images

    Two biotechs set out to end sector's IPO drought

    HilleVax and Belite Bio could soon become the first biotechs to go public in almost two months, representing a key test of investors’ willingness to support emerging life sciences companies.

    By April 27, 2022
  • Image attribution tooltip
    libre de droit via Getty Images

    Solid Bio joins slate of biotech layoffs, shedding 35% of its workforce

    The company is the latest in a growing list of gene therapy developers to restructure and cut jobs during an industry-wide downturn. 

    By April 27, 2022
  • Image attribution tooltip
    DKosig via Getty Images

    Undeterred by gene therapy's struggles, a startup launches into a downturn

    Apertura Gene Therapy, a new company formed by Deerfield, is hoping a suite of next-generation tools will help it stand out at a time when this area of research has fallen out of favor with some public investors.

    By April 26, 2022
  • Nektar begins sweeping layoffs after $2B Bristol Myers deal falls apart

    Loss of the lucrative partnership has triggered a wide-ranging restructuring that will pare down Nektar’s workforce by about 70%.

    By April 26, 2022
  • Image attribution tooltip
    "Calculator" by stevepb is licensed under CC BY-SA 2.0

    Black Diamond, yielding to competitors, scraps its top drug and cuts jobs

    The fast progress of similar targeted cancer medicines led the company, which raised $201 million in an initial public offering just two years ago, to change direction and reduce its workforce by 30%. 

    By April 25, 2022
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive

    Seagen to expand, add jobs with new cancer drug factory

    While some biotechs are restructuring amid a market downturn, SeaGen plans to add 200 positions through a large manufacturing plant that should be operational in 2024.

    By April 21, 2022
  • Image attribution tooltip
    Permission granted by Satellite Bio

    Satellite Bio launches with new approach to bioengineering tissues

    Backed by $110 million in venture funding, Satellite is led by Dave Lennon, formerly head of Novartis Gene Therapies. 

    By April 20, 2022
  • Image attribution tooltip
    utah778 via Getty Images

    Imara to reduce staff by 83% amid biotech shakeout

    The planned job cuts were announced days after Imara — one of three spinouts from the drug accelerator Cydan Development — stopped development of its top medicine.

    By April 18, 2022
  • Image attribution tooltip
    Courtesy of Editas Medicine

    Editas CEO to step down in latest executive change-up

    A little more than a year after taking on the role, Jim Mullen is preparing to pass the torch to Gilmore O'Neill, who has served as the chief medical officer at Sarepta Therapeutics.

    By April 14, 2022
  • Image attribution tooltip
    atiatiati via Getty Images

    ProQR to lay off 30% of staff following eye drug setback

    In the near term at least, the biotech company is pinning hopes for its lead eye disease treatment on a new analysis of a recently failed study.

    By Kristin Jensen • April 13, 2022
  • Image attribution tooltip
    Dr Microbe via Getty Images

    Versant-backed startup launches with plans to broaden cell therapy's reach

    Cimeio Therapeutics, which emerged Wednesday with $50 million in funding, will use "shielding" technology to try to bring stem cell transplants and adoptive cell therapy to more patients.

    By April 13, 2022
  • Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    UK bid to battle antibiotic resistance yields first subscription-style plan

    Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.

    By April 12, 2022
  • Image attribution tooltip
    BioPharma Dive

    AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T's reach

    This year's meeting on early cancer research featured promising study results from German biotechs BioNTech and Affimed as well as details from a "practice-changing" lung cancer trial.

    By , April 11, 2022
  • Image attribution tooltip
    William Walker/BioPharma Dive
    Sponsored by Janssen Oncology

    [Podcast] Breaking Down Barriers: How Bladder Cancer Innovations Benefit Patients and Treatments for Other Diseases

    Recent breakthroughs in bladder cancer treatment are helping patients combat one major challenge to current options — the bladder permeability barrier. These treatments also have implications for other cancers and diseases. This podcast explains how.

    By BioPharma Dive's studioID • April 11, 2022
  • Image attribution tooltip
    Nasdaq

    Biotech startups face 'trickle-down effects' as sector's IPO drought endures

    The slowdown has already forced many biotechs to wait longer to go public. There are early signs private financing deals may be flagging as well.  

    By April 11, 2022
  • Akebia to lay off 42% of workforce, suspend trials after FDA drug rejection

    The layoffs come after safety concerns led the FDA to rebuff its anemia pill, similar to the agency's spurning of FibroGen's rival drug last year.

    By April 7, 2022
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive

    Alnylam to wait longer for FDA verdict on latest RNA drug

    The FDA has yet to sign off on a third-party packaging and labeling facility that Alnylam planned to help launch its drug, called vutrisiran, meaning an approval decision could come as late as mid-July.

    By April 4, 2022
  • Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex gets positive trial results for non-opioid painkiller in boost to pipeline

    After several attempts at designing a drug for acute pain, Vertex has a candidate it's ready to take into late-stage testing following two successful Phase 2 studies.

    By March 31, 2022